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Abstract
Background: Catechol-O-methyltransferase (COMT Val158Met) has been implicated in both depression and
cardiovascular disease. The purpose of this study was to assess if COMT Val158Met, which influences the COMT
enzyme activity, has an effect on the risk of cardiovascular disease (CVD) in individuals with a history of depression
and also to determine if the risk differs depending on gender.
Methods: Data from a longitudinal cohort study of mental health among Swedish adults was used. Depression was
assessed twice 3 years apart for each participant, in 1998–2001 and 2001–2003. Saliva DNA was contributed by
4349 (41.7%) of the participants and 3525 was successfully genotyped for COMT Val158Met. Participants were
followed up until December 2014 from the National Patient register with regard to cardiovascular outcomes
(hypertensive or ischemic heart disease, and stroke).
Results: Those with depression and the high COMT enzyme activity genotype (Val/Val) had almost a three-fold
increased risk of later CVD (OR 3.6; 95% CI: 2.0-6.6) compared to those non-depressed carrying the Val/Val allele. This
effect on risk for CVD was higher in women compared to men (OR 7.0; 95% CI: 3.0-14.0 versus OR 2.1; 95% CI: 1.0-6.
8). Both additive interaction (attributable proportion (AP) = 0.56; 95% CI: 0.24-0.90 and synergy index (SI) = 4.39; 1.018.7) and multiplicative interaction (log likelihood test p = 0.1) was present between depression and COMT
Val158Met in predicting risk of later CVD.
Conclusion: High COMT activity genotype Val158Met increased the risk of CVD in depressed persons. The risk was
higher in women compared to men.
Keywords: Genetic variation, Depression, Myocardial infarction, Stroke, Gender

Background
Epidemiological and family studies have repeatedly
shown that genetic predisposition accounts for 40–60%
of the risk for coronary artery disease. Correspondingly
for depression, twin studies suggest a heritability of 40–
50%, and family studies indicate a two- to threefold
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increase in lifetime risk of developing depression among
first-degree relatives [1]. Multiple studies have shown
that depression is a risk factor for cardiovascular diseases (CVD) including coronary heart disease and stroke
[2]. Thus genetic vulnerability is important in both CVD
and depression, and some of these genetic underpinnings may be shared between the disorders.
Catechol-O-methyltransferase (COMT) has previously
been implicated in both depression and CVD. The enzyme COMT is expressed in several tissues and degrades
not only dopamine but also other catecholamines and
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sex steroids, like catechol estrogens and dietary polyphenols. Animal and human studies have shown that altered
levels of dopamine neurotransmission contribute to
depressive-like behavior and influence depressive symptoms [3, 4]. Dopamine, [5] catechol amines [6, 7] and
estrogens [8] have well-known effects on the cardiovascular system, e.g. blood pressure regulation. The COMT
enzymatic activity is dependent on genetic variations in
the COMT gene. The Val158Met has a large effect on the
enzymatic activity and the minor allele is quite frequent
in many human populations. COMT Val158Met is a substitution of methionine (Met) for valine (Val) at codon
158 encoded by a single nucleotide polymorphism
(SNP), rs4680. The Met allele has a lower enzymatic activity compared to the Val allele. The Val/Val genotype is
associated with approximately 40% more effective degradation of dopamine compared to the Met/Met genotype, while those with Val/Met genotype display an
intermediate COMT activity [9, 10].
Although COMT Val158Met has not shown significance
in genome-wide association studies (GWAS) on depression, a recent meta-analysis by Wang et al. suggested an
effect on major depressive disorder depending on ethnicity, with Val being the vulnerability allele in Europeans
[11, 12]. The COMT Val158Met has also been reported to
be associated with cardiovascular disease and metabolic
disorder. COMT Val158Met homozygosity for the low-activity allele (Met/Met), has been associated with myocardial infarction (ncases = 69, ncontrols = 723) [13] and
metabolic disorders like abdominal obesity and high blood
pressure in men (n = 240) [14]. In contrast, in a larger cohort study in Swedes by Eriksson et al. (ncases = 174, ncontrols = 348), Met/Met was reported to be protective against
myocardial infarction [8]. The purpose of this study was
to determine the effect of COMT Val158Met on the risk of
CVD among depressed persons. Based on the fact that the
Val allele was the risk allele for depression in the meta
analysis in Europeans [11], and Met/Met homozygosity
had a protective effect on myocardial infarction in the
large Swedish cohort [14], we hypothesized that the Val allele might increase the risk for depression leading to
CVD. Because of previous gender-specific associations for
COMT Val158Met with depression and CVD [14–16] we
performed gender-stratified analyses.

Methods
Cohort

This project utilized data from the PART study (In
Swedish short for: Psykisk hälsa, Arbete och RelaTioner),
a longitudinal cohort study of mental health, work and
relations among randomly selected adults (20–64 years)
residing in Stockholm County, Sweden. The Ethical Review Board at Karolinska Institutet, Stockholm, approved
the study (case number: 96–260, 97–313, 01–218, 03–
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302, 2004–528/3, 2009/880–31, 2012/808–32. After a
complete description of the study to the subjects, written
informed consent was obtained. The PART study had
three measurement points: wave 1 (W1) in 1998–2000,
wave 2 (W2) in 2001–2003 and wave 3 (W3) in 2010. At
each wave, participants answered a postal questionnaire.
The questionnaire was divided into two parts, the first one
comprised questions about childhood conditions, socioeconomic and demographic factors, coping-strategies, financial status, working conditions, social network, life
events, somatic disorders and use of medication. The second part included screening instruments for psychological
wellbeing and psychiatric symptoms.
The PART study aimed to include 19,744 persons out of
which 19,457 could be reached, and 10,443 individuals
responded to the questionnaire at W1 (participation rate
53%). Non-response analyses were performed using available administrative registers, and participation was related
to female gender, higher age, higher income and education, being born in the Nordic countries and having no
previous psychiatric diagnosis in inpatient registers [17].
In the following two waves the participation rates were
83% (n = 8622) and 61% (n = 5228). Attrition in W2 was
associated with similar factors as in W1 [18]. All respondents in W1 (n = 10,443) were invited to provide saliva for
DNA and 4349 (42%) participated and were followed up
for occurrence of cardiovascular disease event between
2001 and 2014 in the National Patient Register (NPR) [19]
(Figure 1). Those with previous psychiatric illness were excluded from the non-depressed group (n = 206).

Definition of depression

A participant was assessed as ‘Depressed’ if scored
with depression in W1 or W2 or both waves according to the Major Depression Inventory (MDI) [20].
The MDI has shown high validity in both clinical and
non-clinical samples [21, 22]. The MDI scale comprises 10 questions on symptoms present nearly every
day during the past 2 weeks. Each question has five
response alternatives scored from 1 to 5 according to
the presence of the symptom; all the time (5), most
of the time (4), slightly more than half of the time (3),
slightly less than half of the time (2) some of the
time (1) and never (0). The sum score of all 10 questions ranges from 0 to 50. In both W1 and W2 of
PART, a subsample was interviewed by psychiatrists
using Schedules for Clinical Assessment in Neuropsychiatry to validate the MDI scale for diagnosis of
depression. Using an MDI score cutoff > 20, the sensitivity was 78% and the specificity was 73% for Major
depressive disorder, and 67 and 79%, respectively, for
all depressive disorders [23]. In this current study we
used cutoff MDI > 20 for defining depression.

Almas et al. BMC Medical Genetics (2018) 19:126

Page 3 of 7

Fig. 1 Patient Recruitment for DNA collection from the PART study.

Definition of cardiovascular disease

Statistical analyses

Cardiovascular disease (CVD) was assessed by hospital
discharge diagnoses from the Swedish National Patient
Register (NPR) between 2001 and 2014 [24]. The following diagnoses according to the international classification of diseases (ICD10) were used and were grouped
together as cardiovascular diseases: ischemic/hypertensive heart disease; hypertensive diseases (I11-I13), ischemic heart diseases (I20-I25), heart failure (I50), other
peripheral vascular diseases, embolism and thrombosis
(I73-I74); and stroke (I60-I67 and I69).

Logistic regression was used to calculate odds ratios
(OR) and corresponding 95% confidence intervals
(95% CI) for depression and CVD given COMT Val158Met, adjusting for age and body mass index (BMI). To
determine the combined effect of Val158Met and depression on later CVD, similar logistic regression analyses
were performed using the four dummy variables; Met
carriers (A/A plus A/G) with no depression (reference),
Met carriers (A/A plus A/G) with depression, Val/Val
(G/G) with no depression, and Val/Val (G/G) with depression. Additive interaction was estimated [25] by calculating the following indices [26, 27]: (i) the relative
excess risk due to interaction (RERI), (ii) the attributable
proportion due to interaction (AP) and (iii) the synergy
index (S). RERI is the excess risk due to interaction relative to the risk without exposure. AP refers to the attributable proportion of disease that is due to interaction
among individuals with both exposures. S is the excess
risk from both exposures when the additive interaction,
relative to the risk from both exposures without interaction. RERI ≠ 0, AP ≠ 0, or S ≠ 1 are indicative of additive interaction [28]. Indices results over the null value
indicate synergistic interactions; indices below the null
value indicate antagonistic interactions [26]. Multiplicative interaction was estimated using a main effect model
(depression and COMT Val158Met as exposure) with

DNA sampling and genotyping

In 2006–2007 and 2010–2011, all participants who had
responded in the first wave (W1) were invited to contribute DNA using a self-administered whole-saliva
DNA sample collection kit (Oragene, DNA Genotek
Inc., Ottawa, Canada) sent to their homes. Saliva was
obtained from 4349 (42%) participants and genomic
DNA was extracted using Oragene Purifier. The COMT
Val158Met (rs4680) genotype was successfully obtained
for 3731 samples (91% of the randomly selected 4107
samples) using TaqMan SNP genotyping assays applying
an ABI 7900 HT instrument (Applied Bio systems, Foster City, CA) [15]. Of 1443 samples run in duplicate
plates, 96% had successful and identical result in both
plates.
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and without multiplicative interaction term between depression and COMT Val158Met. The relative goodness of
fit among models was established by the Loglikelihood
test using the main effect model as reference. A p-value of
0.05 was considered to be statistically significant for the
main effects; and a p-value of 0.10 was considered to be
statistically significant for interaction terms and interaction indices, since epidemiologic data have limited
power to detect product terms [29, 30]. SPSS versions
19.11 and SAS 9.3 were used for the statistical analyses.

Results
Out of the 3525 participants with COMT Val158Met
data 1094 (31.0%) had Met/Met genotype, 1720 (48.0%)
were Met/Val and 711 (20.2%) were Val/Val (Table 1).
The genotype distribution was in Hardy Weinberg
equilibrium (p = 0.31). Those homozygous for Val/Val
showed a borderline reduced risk for depression (OR =
0.70 (95% CI: 0.60-1.0), Table 2). However, those who
were Val/Val had a point-wise increased risk for future
CVD (OR = 1.3 (95% CI: 1.0-1.7)). Stratification on gender showed that the OR point estimate for risk for later
CVD was higher among women than men (OR = 1.5
(95% CI: 0.8-2.4) and OR = 1.1 (95% CI: 0.7-1.7), respectively, Table 2).
Also, depression had a main effect increasing the risk
for CVD in this cohort (OR = 1.9 (95% CI 1.4-2.5)) [31].
Considering both depression and Val158Met genotype for
future risk of CVD, the OR was 3.6 (95% CI: 2.0-6.6))
for those having both Val/Val and depression and 1.1
(95% CI: 0.8-1.6) for those having Val/Val and no depression (Table 3). The OR (95% CI) for those who were
Met carriers and had depression was 1.5 (1.0-2.3). We
also stratified the data by gender and found that the
point-wise effect on risk of later CVD was higher in
women compared to men among those having both Val/
Val and depression; OR 7.0 (3.0-14) and 2.1 (1.0-6.8), respectively (Table 3). To explore the possibility of a
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dilution effect by having Met/Met plus Val/Met in the
reference group, we calculated the OR for having Val/
Val and depression using the reference group being
those having Met/Met and no depression. This OR was
4.2 (95% CI 2.1-8.4) for men and women together, and
8.5 (95% CI 3.4-21.2) for women only. This indicated a
slight but no major dilution effect by including both
Met/Met and Met/Val in the reference group (corresponding ORs being 3.6 and 7.0, respectively, Table 3).
Indices of additive interaction in the sample demonstrating additive interaction between depression and
Val158Met genotype for later CVD are shown in Table 4.
For multiplicative interaction, effect size of the interaction term and the loglikelihood test comparing the
main effect model and the model with interaction term
are shown in Table 4 and indicate borderline statistical
significance.

Discussion
Depression is a known risk factor for CVD [31–33]. The
COMT Val158Met genetic variation influencing COMT
enzyme activity has previously been associated with risk
for depression [12], and risk for CVD [8, 13, 14]. The
identity of the at risk allele has varied between studies,
although a meta-analysis demonstrated high activity
COMT Val allele as risk allele for depression. An influence of gender as well as childhood adversity on the
Val158Met association with depression has previously
been reported [15], although a recent meta-analysis
found no Val158Met association to depression in any
gender [16]. Using a large population-based Swedish cohort of adults we here show for the first time that the
COMT Val158Met genotype, corresponding to high
COMT enzymatic activity, implies an increased risk of
CVD especially for those who had depression up to
14 years earlier. Thus, both an additive and a multiplicative interaction between depression and COMT Val158Met for risk of CVD were detected. Additionally, this

Table 1 Distribution of COMT Val158Met, depression and cardiovascular disease (CVD), stratified by gender
All (n = 3525)

Men (n = 1495)

Women (n = 2030)

n (%)
Depression

556 (15.8)

157 (10.5)

399 (19.7)

Cardiovascular disease

236 (6.7)

152 (10.2)

84 (4.1)

Met/Met

1094 (31.0)

457 (30.6)

637 (31.4)

Met/Val

1720 (48.0)

722 (48.3)

998 (49.2)

Val/Val

711 (20.2)

316 (21.1)

395 (19.5)

46 (34, 55)

47 (35, 55)

45 (33, 54)

24.5 (22.5, 26.9)

25.3 (23.4, 27.4)

23.8 (22.0, 26.5)

COMT Val

158

Met

a

Median (25th, 75th percentile)
Age [years]
BMI [kg/m2]
a

b

Met/Met (A/A), Met/Val (A/G), Val/Val (G/G)
b
BMI: Body mass index

Almas et al. BMC Medical Genetics (2018) 19:126
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Table 2 Association of COMT Val158Met with depression and cardiovascular disease; stratified by gender
COMT Val158Met

Depression

Cardiovascular disease (CVD)

All n = 556

Men n = 157

Women n = 399

All n = 236

n Depressed/n Non-depressed
Met/Met or Met/Val
Val/Val

n CVD/n

Men n = 152

Womenn = 84

Non-CVD

463/2351

130/1049

333/1302

179/2635

117/1062

62/1573

93/618

27/289

66/329

57/654

35/281

22/373

Odds ratio (95% confidence interval)a
Met/Met or Met/Val

1 (ref)

1 (ref)

1 (ref)

1 (ref)

1 (ref)

1 (ref)

Val/Val

0.70 (0.60-1.0)

0.74 (0.50-1.1)

0.78 (0.60-1.0)

1.3 (1.0-1.7)

1.1 (0.7-1.7)

1.5 (0.8-2.4)

p value

0.02

0.20

0.11

0.13

0.60

0.13

a

Odds ratio (OR) for Val/Val (G/G) was assessed relative to the reference: Met/Met (A/A) plus Met/Val (A/G), adjusted for age and body mass index

risk of CVD by high COMT activity genotype and depression was more pronounced in women compared to
men. Both mild and severe depression were considered,
scored at two time points for each participant, and the
original cohort was randomly selected among Swedish
nationals in the Stockholm County.
There are previous reports demonstrating a relationship between COMT Val158Met and acute coronary
events, ischemic stroke and CVD risk factors like hypertension and lipid abnormalities [13, 14, 34]. The results
from these studies are however not fully consistent with
regard to which allele implies a disease risk and the influence of depression on the relationship was not previously assessed. Hagen and coworkers reported that high
COMT activity (Val/Val genotype) is overrepresented in
male and female Norwegians with systolic hypertension
(≥140 mmHg) (n = 2591) [34]. This finding was confirmed in a Chinese population (n = 3079) showing that
high activity COMT (Val/Val) was associated with cardio
-metabolic risk factors including hypertension and high
triglyceride levels [35]. Accordingly, Eriksson et al. reported a protective effect of low activity COMT (Met/
Met or Val/Met) against myocardial infarction in Swedish and Finnish hypertensive men (n = 522) [8]. Contrary

to this, low activity COMT (Met/Met or Val/Met) was
associated with acute coronary events in Finnish men
(n = 792) [13], and with high systolic and diastolic blood
pressure and abdominal obesity in Swedish men (n =
1302) [14]. The reason for the discrepancy in risk allele
identity between the aforementioned studies is unclear
but could in part be related to different ranges of estrogen levels, and thereby different gender and age distributions. Accordingly, we found that high activity COMT
(Val/Val)*depression was associated with increased CVD
risk in women, but not in men. This sex-based difference might partially be explained by the difference in estrogen activity between men and women. Estrogen plays
an important role in the cardiovascular system and
COMT is key in the degradation of estrogens. Thus, the
association between COMT Val/Val and CVD in females
might reflect altered levels of estrogen and its metabolites [8, 36]. Moreover, estrogen signaling influences
COMT transcription through estrogen response elements in the COMT promoter [37, 38]. The COMT enzyme metabolizes also dopamine and catecholamines
which regulate both mood and cardiovascular functions
through wide-spread expression of their receptors.
Therefore, our Val/Val-CVD association finding may

Table 3 Interaction between COMT Val158Met and depression for later cardiovascular disease (CVD), stratified by gender
All (n = 3525)

Depression
No
Yes

Men (n = 1495)

Women (n = 2030)

Met/Met or Met/Val

Val/Val

Met/Met or Met/Val

Val/Val

Met/Met or Met/Val

Val/Val

n = 2814

n = 711

n = 1179

n = 316

n = 1635

n = 395

146 /2205

42/576

102/947

31/258

44/1258

11/318

33/430

15/78

15/115

4/23

18/315

11/55

1.0 (0.50 2.0)

n CVD/n

Non-CVD

Odds ratio (95% confidence interval)a
Depression

a

No

1 (Ref)

1.1 (0.8 1.6)

1 (Ref)

1.1 (0.73 1.7)

1 (Ref)

P values

–

0.5

–

0.5

–

0.10

Yes

1.5 (1.0-2.3)

3.6 (2.0-6.6)

1.8 (1.0-3.4)

2.1 (1.0 6.8)

2.0 (1.1 3.5)

7.0 (3.0 14.0)

P values

0.03

< 0.001

0.05

0.20

0.01

< 0.001

Odds ratio (OR) for Val/Val (G/G) with no depression, Val/Val (G/G) with depression, and Met carriers (A/A plus A/G) with depression, adjusted for age and body
mass index. Met carriers (A/A plus A/G) with no depression was the reference group
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Table 4 Additive and multiplicative interaction analyses
between COMT Val158Met and depression for later
cardiovascular disease (CVD) (n = 3525)
Interaction indices

Estimate (95% CI)

data from the cause of death register and the outpatient
register, hence we might have missed those who died or
visited outpatient department due to IHD or stroke
without prior hospitalizations.

Additive interactiona
RERI

2.06 (− 0.22-4.3)

AP

0.56 (0.24-0.88)

S

4.39 (1.0-18.7)

Multiplicative interaction

Odds ratio (95% CI)

Model 1 - main effects
Depression (yes)

1.4 (1.0-2.0)

Val/Val

1.3 (1.0-1.8)

Model 2 – main and interaction effects
Depression (yes)

1.2 (0.70-1.7)

Val/Val
Depression x Val

Conclusion
The risk for later CVD was increased in depressed persons with high activity COMT Val158Met genotype (Val/
Val), with a synergistic interaction between depression
status and COMT genotype. This effect on risk for CVD
was higher in women and might in part reflect estrogen
signaling. The findings warrant further studies.
Abbreviations
CVD: Cardiovascular diseases; HTN: Hypertension; IHD: Ischemic heart
Diseases; MDI: Major depression inventory

1.1 (0.80-1.6)
158

Met

P-value (Model 2 versus Model 1)

2.2 (1.0-4.7)
0.10b

a
RERI: the relative excess risk due to interaction
AP the attributable proportion due to interaction
S the synergy index
AP > 0 and S > 1 indicate additive interaction
b
Log likelihood test (− 2 log likelihood: Model 1 = 1725.6; Model 2 = 1721.2)

partly be due to effects of COMT enzyme activity variation on the metabolism of these transmitters. The influence of depression on the Val/Val-CVD association may
in part be through increased inflammation and oxidative
stress often seen in the depressed state, [39] which could
potentiate a high COMT enzyme activity effect on cardiovascular function. Of the individuals in PART 11% had a
non-Swedish origin, among those the vast majority had a
Nordic origin. The Swedish population at time of sampling had no strong internal genetic borders [40] and especially the southern/middle parts of Sweden (from where
the participants of this study are derived) were more genetically homogeneous [41].
Limitations

Firstly, due to the self-administered sampling at home,
the depression cases that participated did likely not represent those most severely depressed. Secondly, only
42% provided DNA samples. Factors associated with
public refusal to consent to DNA biobanking in the
PART have been reported and reveal that, a lack of personal relevance of DNA contribution and feelings of discomfort related to the DNA being used for purposes
other than the respective study were the reasons for low
participation [42] The association between depression
and risk of later CVD is unlikely influenced by refusal to
consent to DNA biobanking. Another limitation of the
study is that we did not have individual data on psychotropic drugs medication. Antipsychotic drugs are known
to increase risk for CVD [43]. Also, we did not include
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